ATTAIN-1
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
Definition
The phase 3 of orforglipron (Foundayo) for chronic weight management in adults with obesity and without diabetes: 72 weeks, N=3,127, ten countries (NCT05869903). Primary outcome −12.4% body weight on 17.2 mg against −0.9% placebo on the efficacy estimand, and −11.1% against −2.1% on the treatment-regimen estimand. It drove the April 2026 approval. ⚠ Which estimand a seller quotes changes the headline by more than a point.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.
Other terms under Major trials
Where the evidence lives
- Foundayo drug overview
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers